The effectiveness and tolerability of clobazam in the pediatric population: Adjunctive therapy and monotherapy in a large-cohort multicenter study
- PMID: 35749975
- DOI: 10.1016/j.eplepsyres.2022.106963
The effectiveness and tolerability of clobazam in the pediatric population: Adjunctive therapy and monotherapy in a large-cohort multicenter study
Abstract
Objective: To evaluate the effectiveness and tolerability of clobazam therapy in the pediatric population in terms of seizure semiology, epileptic syndromes, and etiological subgroups.
Methods: A retrospective cohort study was conducted consisting of 1710 epileptic children from eight centers in seven geographic regions of Turkey. The initial efficacy of clobazam therapy was evaluated after three months of treatment. The long-term effectiveness of the drug, overall seizure outcomes, and overall therapeutic outcomes were evaluated during 12 months of therapy.
Results: Analysis of initial efficacy after the first three months of clobazam therapy showed that 320 (18.7 %) patients were seizure-free, 683 (39.9 %) had > 50 % seizure reductions, and 297 (17.4 %) had < 50 % seizure reductions. A positive response (seizure-free and >50 % seizure reduction) was determined for focal-onset (62.3 %) seizures, epileptic spasms (61.5 %), and generalized onset seisures (57.4). The highest positive response rate among the epileptıc syndromes was for self-limited epilepsy with centrotemporal spikes (SeLECTS). The highest negative response rate was for developmental and/or epileptic encephalopathies (DEEs). Magnetic resonance imaging (MRI) revealed a structural etiological diagnosis in 25.8 % of the cohort. A higher positive response rate was observed at MRI in patients with sequelae lesions than in those with congenital lesions. The seizure recurrence rate was higher in the patient group with epilepsy wıth genetic and metabolic causes, in individuals with more than one seizure type, and in those using three or more antiseizure drugs.
Conclusions: This cohort study provides additional evidence that clobazam is an effective and well-tolerable drug with a high seizure-free rate (18.7 %), a significant seizure reduction rate (57.3 %), and with excellent overall therapeutic outcomes with a low seizure relapse rate and considerable reversible benefits in the pediatric population.
Keywords: Childhood epilepsy; Clobazam; Lennox-Gastaut syndrome; Reversible effect of clobazam; West syndrome.
Copyright © 2022 Elsevier B.V. All rights reserved.
Similar articles
-
Clobazam as add-on therapy in children with epileptic encephalopathy.Can J Neurol Sci. 2006 May;33(2):209-13. Can J Neurol Sci. 2006. PMID: 16736732
-
Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years.Epilepsia. 2014 Apr;55(4):558-67. doi: 10.1111/epi.12561. Epub 2014 Mar 1. Epilepsia. 2014. PMID: 24580023 Free PMC article. Clinical Trial.
-
West syndrome and other infantile epileptic encephalopathies--Indian hospital experience.Brain Dev. 2002 Mar;24(2):130-9. doi: 10.1016/s0387-7604(02)00029-3. Brain Dev. 2002. PMID: 11891107
-
Summary of recommendations for the management of infantile seizures: Task Force Report for the ILAE Commission of Pediatrics.Epilepsia. 2015 Aug;56(8):1185-97. doi: 10.1111/epi.13057. Epub 2015 Jun 30. Epilepsia. 2015. PMID: 26122601 Review.
-
Clobazam : in patients with Lennox-Gastaut syndrome.CNS Drugs. 2012 Nov;26(11):983-91. doi: 10.1007/s40263-012-0007-0. CNS Drugs. 2012. PMID: 23034582 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical